Lifeward Ltd. Form 8-K Summary
Business Context and Reporting Period
Lifeward Ltd. (LFWD), a company incorporated in Israel with principal offices in Massachusetts, filed this Current Report on Form 8-K on February 12, 2026. The filing discloses the entry into a material definitive agreement and the creation of a direct financial obligation.
Key Financial Metrics and Debt
This filing does not report revenue, profit, cash flow, or operating margins. The primary financial disclosure relates to debt obligations:
- New Debt: Entered into a Secured Promissory Note with Oramed Pharmaceuticals, Inc. for an initial principal amount of $525,000.
- Debt Capacity: The principal amount may be increased by up to an additional $975,000 upon mutual consent.
- Interest Rate: 24% per annum.
- Security: The note is secured by a lien on the Company's cash.
- Existing Debt: A prior Secured Promissory Note with Oramed Ltd. in the principal amount of $3.0 million remains outstanding.
- Collateral Application: Proceeds from the collateral will be applied to both the initial and subsequent notes on a ratable basis.
Material Changes and Terms
The material change is the incurrence of new short-term debt secured by company cash. Key terms include:
- Maturity Date: The earlier of August 12, 2026, or the failure to obtain shareholder approval for specific transactions (Securities Purchase Agreement and Share Purchase Agreement dated January 12, 2026).
- Covenants: The agreement limits additional indebtedness, liens, mergers, asset sales, and affiliate transactions.
- Events of Default: Includes non-payment, covenant breaches, insolvency, bankruptcy, or a material adverse effect on the Company.
- Remedies: Upon default, Oramed may accelerate payment, increase interest rates, and terminate commitments.
Outlook, Risks, and Contingencies
The repayment of the new note is contingent on the Company obtaining shareholder approval for pending transactions by the outside dates set forth in the January 2026 agreements. Failure to secure this approval triggers immediate maturity. The filing highlights significant liquidity risk due to the lien on cash and the high interest rate (24%). The full text of the note is expected to be filed as an exhibit to the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Investor Verification Checklist
- Verify the status of shareholder approval for the January 12, 2026 Securities Purchase Agreement and Share Purchase Agreement.
- Confirm the current cash balance available to service the $3.525 million total secured debt obligation.
- Review the upcoming Form 10-K for the full text of the Subsequent Secured Promissory Note.
- Assess the impact of the 24% interest rate on future liquidity and profitability.